Table 2.
Correlation of p15, p16, MGMT, and DAPK methylation status with clinicopathological features in DLBCL
| Variable | p15m | p16m | MGMTm | DAPKm | p |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 4/26 (15%) | 9/26 (35%) | 11/26 (42%) | 14/26 (54%) | |
| Female | 8/25 (32%) | 10/25 (40%) | 9/25 (36%) | 14/25 (56%) | NS |
| Age (yr) | |||||
| ≤60 | 10/30 (33%) | 14/30 (47%) | 14/30 (47%) | 19/30 (63%) | |
| >60 | 2/21 (9%)* | 5/21 (24%) | 6/21 (29%) | 9/21 (43%) | 0.091* |
| Stage | |||||
| I, II | 2/8 (25%) | 4/8 (50%) | 2/8 (25%) | 5/8 (62%) | |
| III, IV | 10/43 (23%) | 15/43 (35%) | 18/43 (42%) | 23/43 (53%) | NS |
| LDH | |||||
| Normal | 7/20 (35%)** | 11/20 (55%)* | 7/20 (35%) | 12/20 (60%) | 0.035* |
| Elevated (>450 u/L) | 4/29 (14%) | 6/29 (21%) | 12/29 (41%) | 14/29 (48%) | 0.090** |
| Extranodal sites | |||||
| 0, 1 | 10/39 (26%) | 14/39 (36%) | 14/39 (36%) | 20/39 (51%) | |
| >1 | 2/12 (17%) | 5/12 (42%) | 6/12 (50%) | 8/12 (67%) | NS |
| ECOG performance status | |||||
| <2 | 10/35 (29%)* | 14/35 (40%) | 13/35 (37%) | 21/35 (60%) | |
| ≥2 | 2/16 (12%) | 5/16 (31%) | 7/16 (44%) | 7/16 (45%) | 0.095* |
| IPI score | |||||
| Low/intermediate low | 7/17 (41%)** | 10/17(59%)* | 7/17 (41%) | 12/17 (71%) | 0.034* |
| Intermediate high/high | 5/34 (15%) | 9/34 (26%) | 13/34 (38%) | 16/34 (47%) | 0.076** |
| B symptoms | |||||
| Absent | 4/16 (25%) | 7/16 (44%) | 4/16 (25%) | 8/16 (50%) | |
| Present | 7/33 (21%) | 12/33 (36%) | 15/33 (45%) | 18/33 (54%) | NS |
| BM involvement | |||||
| Absent | 9/32 (28%) | 13/32 (41%) | 13/32 (41%) | 20/32 (62%) | |
| Present | 3/19 (16%) | 6/19 (32%) | 7/19 (37%) | 8/19 (42%) | NS |
| Bulky tumor (≥10 cm) | |||||
| Absent | 9/38 (24%) | 15/38 (39%) | 15/38 (39%) | 21/38 (55%) | |
| Present | 3/11 (27%) | 4/11 (36%) | 4/11 (36%) | 5/11 (45%) | NS |
| Bcl‐2 expression | |||||
| Absent | 6/28 (21%) | 11/28 (39%) | 9/28 (32%) | 14/28 (50%) | |
| Present | 4/18 (22%) | 4/18 (22%) | 8/18 (44%) | 9/18 (50%) | NS |
| Bcl‐6 expression | |||||
| Absent | 1/12 (8%) | 5/12 (42%) | 5/12 (42%) | 7/12 (58%) | |
| Present | 5/23 (22%) | 8/23 (35%) | 6/23 (26%) | 11/23 (48%) | NS |
| CD10 expression | |||||
| Absent | 1/12 (8%) | 4/12 (33%) | 5/12 (42%) | 6/12 (50%) | |
| Present | 3/11 (27%) | 3/11 (27%) | 5/11 (45%) | 7/11 (64%) | NS |
| Ki67 expression | |||||
| Weak/moderate | 3/15 (20%) | 5/15 (33%) | 5/15 (33%) | 7/15 (47%) | |
| High | 6/21 (29%) | 7/21 (33%) | 8/21 (38%) | 12/21 (57%) | NS |
| Response to treatment | |||||
| CR/PR | 10/41 (24%) | 14/41 (34%) | 16/41 (39%) | 21/41 (51%) | |
| NR | 1/8 (12%) | 4/8 (50%) | 3/8 (37%) | 6/8 (75%) | NS |
| Relapse | |||||
| Absent | 11/31 (35%)* | 13/31 (42%) | 10/31 (32%) | 17/31 (55%) | |
| Present | 0/18 (0%) | 5/18 (28%) | 8/18 (44%) | 8/18 (44%) | 0.001* |
| Death outcome within 5 years | |||||
| Absent | 9/27 (33%)* | 11/27 (41%) | 10/27 (37%) | 16/27 (59%) | |
| Present | 2/20 (10%) | 6/20 (30%) | 8/20 (40%) | 9/20 (45%) | 0.086* |
LDH = lactate dehydrogenase; ECOG = Eastern Cooperative Oncology Group; BM = bone marrow; CR = complete remission; PR = partial remission; NR = no response; NS = not significant. * and ** relates significant p values with appropriate gene and examined clinicopathological characteristics. For the cases where methylation status of two genes is related to appropriate clinicopathological characteristic (LDH and IPI score), * relates appropriate p value with p16 gene, and ** with p15 gene.